Intracerebral hemorrhage accounts for ~10–15% of all strokes, with an annual U.S. incidence of ~80,000 cases and a 30-day mortality of 30–40%. [1] The following is a comprehensive, clinically actionable summary organized for emergency medicine and primary care workflows.
The following figure illustrates the acute ICH management workflow, emphasizing the simultaneous "ABC" approach (Assess Alertness, optimize Blood pressure, Correct Coagulopathy):
1. History
- Time of symptom onset (or last known normal) — critical for guiding acute interventions [3]
- Symptom characterization: acute-onset focal neurological deficit evolving over minutes (not instantaneous as in embolic stroke), headache, nausea/vomiting, altered consciousness [1][4]
- Progression: symptoms typically worsen over the first hours; ~25% deteriorate in transport, another ~25% in the ED [5]
- Associated symptoms: seizure at onset (~more common than in ischemic stroke), speech difficulty, visual changes [5-6]
- Important negatives: absence of headache/vomiting/depressed consciousness makes hemorrhage less likely but does not exclude it — imaging is always required [7-8]
- Medication history: anticoagulants (warfarin, DOACs), antiplatelets, time of last dose [3]
- Substance use: cocaine, amphetamines, alcohol (binge pattern) [3-4]
- Cognitive decline/dementia history (raises suspicion for cerebral amyloid angiopathy) [3]
2. Alarm Features
- Rapid neurological deterioration — suggests hematoma expansion (occurs in ~1 in 3 patients within the first hours) [9]
- Coma or motor posturing — massive supratentorial hemorrhage, brainstem involvement, or acute hydrocephalus [1][10]
- Loss of pupillary reactivity — transtentorial herniation [6]
- Neck stiffness — intraventricular extension with subarachnoid blood [4][7]
- New-onset seizure with depressed consciousness [5]
- GCS ≤8 (OR 4.37 for hemorrhagic vs. ischemic stroke) [8]
- Dysautonomia: central fever, hyperventilation, hyperglycemia, bradycardia [10]
3. Medications
Relevant contributors
- Warfarin, DOACs (rivaroxaban, apixaban, dabigatran, edoxaban), heparin/LMWH — all increase risk of hematoma expansion [1][3]
- Antiplatelet agents (aspirin, clopidogrel) — associated with ED deterioration [5]
- Cocaine and sympathomimetics [3]
Acute reversal agents
- Warfarin (VKA): 4-factor PCC + IV vitamin K (preferred over FFP) [9][11]
- Dabigatran: Idarucizumab (5 g IV); if unavailable, aPCC or 4-F PCC ± hemodialysis [3][11]
- Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban): 4-F PCC or aPCC (note: andexanet alfa was withdrawn from the U.S. market due to unresolved safety concerns) [11-12]
- Heparin/LMWH: Protamine [11]
Contraindicated/harmful
- Platelet transfusion in antiplatelet-associated ICH (without need for neurosurgery) — associated with doubled mortality (PATCH trial) [1]
- Prophylactic corticosteroids — no benefit [3]
- Venous vasodilators (e.g., nitroglycerin) — potentially harmful for BP management [9][13]
4. Diet
- NPO initially until dysphagia screening is completed (early dysphagia screening is recommended) [5]
- Long-term: low-sodium diet, high fruit/vegetable intake — modifiable risk factors for ICH recurrence [4][14]
- Alcohol moderation — binge drinking is a significant risk factor [4]
- Adequate hydration, particularly in patients at risk for cerebral venous thrombosis
5. Review of Systems
- Neurological: headache (severity, onset), vision changes, speech difficulty, weakness/numbness, gait instability, seizure activity
- Cardiovascular: chest pain, palpitations, dyspnea (cardiac complications occur in ~13% of ICH patients) [15]
- GI: nausea/vomiting (raised ICP), dysphagia
- Constitutional: fever (central dysautonomia vs. infection)
- GU: pregnancy status in women of childbearing age (eclampsia, HELLP, cerebral venous thrombosis) [3]
6. Collateral History and Family History
- Collateral from witnesses: exact time of onset, witnessed seizure, fall/trauma, preceding activities
- Prior cognitive decline or dementia (cerebral amyloid angiopathy) [3]
- Family history of hemorrhagic stroke, cerebral aneurysm, AVM, coagulopathy
- Known hypercoagulable states, recent pregnancy/postpartum [5]
- Social context: living situation (affects disposition planning), substance use history
7. Risk Factors
- Hypertension — strongest modifiable risk factor across most populations [1][16]
- Age — incidence increases with age; risk ~2× higher in Asian populations, ~1.6× higher in Black and Hispanic persons vs. White persons in the U.S. [1]
- Anticoagulant use — especially VKAs; DOACs carry lower but non-negligible risk [1]
- Cerebral amyloid angiopathy — major cause in elderly, especially lobar ICH [1][9]
- Excessive alcohol use (binge pattern), cocaine/sympathomimetic use [4]
- Smoking, diabetes, high BMI [14]
- Liver disease, uremia, hematologic disorders — associated coagulopathy [3]
8. Differential Diagnosis
- Ischemic stroke — cannot be reliably distinguished clinically; imaging is mandatory [4][7]
- Subarachnoid hemorrhage — thunderclap headache, meningismus; may coexist with ICH
- Hemorrhagic transformation of ischemic infarct — especially post-thrombolysis [17]
- Intracranial tumor (primary or metastatic) — hemorrhage-prone tumors include melanoma, renal cell, choriocarcinoma [4]
- Cerebral venous sinus thrombosis — consider in young patients, pregnancy, hypercoagulable states [5]
- Arteriovenous malformation / aneurysm rupture — younger patients without hypertension [3]
- Reversible cerebral vasoconstriction syndrome (RCVS) — thunderclap headache, recurrent [9]
- Subdural/epidural hematoma — trauma history, different imaging pattern
- Cerebral cavernous malformation [18]
9. Past Medical History
- Prior stroke (ischemic or hemorrhagic) — recurrence risk
- Chronic hypertension — duration, control, medication adherence
- Atrial fibrillation and anticoagulation status
- Known vascular malformations, aneurysms
- Coagulopathy, thrombocytopenia, liver disease
- Dementia/cognitive impairment (cerebral amyloid angiopathy marker) [3]
- Prior neurosurgical procedures
- Chronic kidney disease (affects coagulation, drug dosing)
10. Physical Exam
Vital signs
- 90% present with acute hypertension exceeding 160/100 mm Hg [10]
- Assess airway, breathing, circulation immediately [3]
Focused neurological exam
- GCS — essential for ICH Score and triage [19]
- NIHSS — quantifies deficit severity; baseline NIHSS ≥10 optimal for predicting poor 90-day outcomes [20]
- Pupillary reactivity — unilateral dilation suggests herniation
- Eye movement abnormalities: gaze preference (basal ganglia), downward/inward deviation with miotic pupils (thalamic), ocular bobbing (pontine) [1]
- Motor exam: hemiplegia pattern localizes hemorrhage
- Cerebellar signs: ataxia, dysmetria, truncal instability (cerebellar hemorrhage) [1]
Concerning findings
- Bilateral Babinski signs — hemorrhage extending beyond single vascular territory [7]
- Cushing triad (hypertension, bradycardia, irregular respirations) — impending herniation
11. Lab Studies
Per AHA/ASA guidelines, the recommended initial workup includes: [3]
- CBC — anemia associated with poor outcomes and hematoma expansion
- PT/INR, aPTT — identify coagulopathy; INR ≥1.4 on VKA triggers reversal [11]
- DOAC-specific assays (anti-Xa level, dilute thrombin time) when appropriate
- BMP (BUN, creatinine, glucose) — hyperglycemia worsens outcomes
- LFTs — hepatic coagulopathy
- Cardiac troponin — elevated in 20–40% of ICH patients; associated with increased mortality [21-22]
- Urine toxicology — cocaine, amphetamines [3]
- Pregnancy test in women of childbearing age [3]
- Type and screen — in anticipation of possible surgery or transfusion
- Inflammatory markers (ESR/CRP) — if vasculitis suspected
12. Imaging
First-line: Non-contrast CT head — rapid, widely available, high sensitivity/specificity for acute ICH [3-4]
- Identifies hemorrhage location, volume (ABC/2 formula), intraventricular extension, hydrocephalus, midline shift
- NCCT markers predicting hematoma expansion: spot sign (on CTA), blend sign, swirl sign, island sign, heterogeneous density, irregular margins [3][23]
CT angiography (CTA)
- Recommended for patients <70 years with lobar ICH, <45 years with any ICH location, or 45–70 years without hypertension history — to exclude macrovascular cause (AVM, aneurysm, dural fistula) [1][3]
- Spot sign on CTA predicts hematoma expansion (61% expansion rate with spot sign vs. 22% without) [5]
MRI
- Equivalent to CT for detecting acute ICH; superior for chronic hemorrhage and identifying underlying pathology (cerebral amyloid angiopathy, cavernous malformation, tumor) [3-4]
- Typically performed in subacute phase
Digital subtraction angiography (DSA): Gold standard for macrovascular causes, especially in young patients [3][9]
Repeat imaging
- Follow-up CT at ~6 and 24 hours to assess for hematoma expansion, hydrocephalus, edema [3]
- Repeat vascular imaging at 3 months to exclude lesions initially compressed by hematoma [9]
13. Special Tests
Scoring systems
- ICH Score — GCS, age ≥80, infratentorial origin, ICH volume ≥30 mL, IVH presence; predicts 30-day mortality (score 0 = 0% mortality; score 5 = 100% mortality) [19]
- ABC/2 formula — bedside estimation of hematoma volume from CT [3]
- NIHSS — baseline ≥10 optimal for predicting death or major disability at 90 days [20]
- ICH Score recalculated at 6 hours improves prognostic accuracy (AUC 0.914 vs. 0.890 at admission) [24]
Point-of-care
- Bedside glucose
- Point-of-care INR
- Continuous EEG — recommended for patients with depressed consciousness to detect subclinical seizures [1]
14. ECG
ECG abnormalities are present in 56–96% of ICH patients: [22][25]
- QTc prolongation (19–67%) — most common; associated with IVH and hematoma volume >30 mL [22]
- ST depression (19–41%) — associated with thalamic location and insular involvement [22]
- T-wave inversion, "cerebral T waves" [21][26]
- ST elevation, pathological Q waves, bundle branch block — must exclude primary cardiac pathology [26]
- Arrhythmias: sinus tachycardia, atrial fibrillation (less common than in ischemic stroke), premature ventricular complexes [15][21]
- QT prolongation increases risk of life-threatening ventricular arrhythmias — warrants continuous cardiac monitoring [26]
ECG changes typically peak at 24 hours and are often transient, driven by sympathetic surge. [26]
15. Assessment
Clinical summary
ICH is a neurological emergency with high early mortality driven by hematoma expansion, which occurs in ~33% of patients within the first hours. [9] The 30-day mortality is 30–40%, and most survivors have significant disability. [1]
Severity stratification
- Mild-moderate: GCS 13–15, small hematoma (<30 mL), no IVH — best candidates for aggressive BP management and bundle of care [3][27]
- Severe: GCS 5–12, large hematoma (>30 mL), IVH, midline shift — consider minimally invasive surgery for supratentorial ICH [9]
- Critical: GCS 3–4, massive hemorrhage, herniation signs — very high mortality; avoid premature withdrawal of care in first 24–48 hours [1-2]
Complications
- Hematoma expansion (first 24 hours) [23]
- Hydrocephalus (especially with IVH) [10]
- Perihematomal edema (days to weeks) [9]
- Seizures [6]
- VTE (DVT/PE) — 4× higher risk than ischemic stroke [3]
- Cardiac complications (stroke-heart syndrome) — ~13% [15]
- Aspiration pneumonia, infections
16. Treatment Plan
Initial stabilization (first 60 minutes — "Golden Hour")
- ABCs: airway protection (intubate if GCS ≤8), adequate oxygenation
- Immediate non-contrast CT head
Blood pressure management
- Target SBP ~140 mm Hg for mild-moderate ICH (SBP 150–220 mm Hg at presentation), achieved within 1 hour with smooth, sustained control [9][13]
- Avoid SBP <130 mm Hg — potentially harmful [9]
- For SBP >220 mm Hg: cautious, modest lowering to 160–180 mm Hg range [13]
- Preferred agents: IV nicardipine (5 mg/h, titrate by 2.5 mg/h q5–15 min, max 15 mg/h) or IV labetalol (10–20 mg bolus, then infusion) [9][13]
- Avoid venous vasodilators (nitroglycerin) [9]
- Minimize BP variability and avoid drops ≥60 mm Hg within 1 hour [28]
Anticoagulant reversal (administer based on suspected use, do not wait for lab results): [3]
Bundle of care (INTERACT3 approach)
Simultaneous early intensive BP lowering + glucose control + antipyrexia + anticoagulation reversal within 6 hours — improved functional outcomes at 6 months. [9][27]
Surgical intervention
- Cerebellar hemorrhage >3 cm (or >15 mL) with neurological deterioration, brainstem compression, or hydrocephalus → immediate surgical evacuation ± EVD [3][9]
- Supratentorial ICH >20–30 mL with GCS 5–12 → consider minimally invasive surgery (reduces mortality, though functional outcome benefit uncertain) [9]
- IVH with hydrocephalus → EVD [5]
- Conventional craniotomy for supratentorial ICH has not shown clear benefit [9]
Supportive care
- DVT prophylaxis: IPC devices from day of diagnosis; pharmacological prophylaxis (LMWH/UFH) can be started 48–96 hours after onset once hemorrhage stability is documented on CT [3]
- Graduated compression stockings alone are not effective [3]
- No prophylactic antiseizure medications — treat only clinical or electrographic seizures [3][5]
- Continuous EEG for patients with depressed consciousness [1]
- Glucose control, normothermia, early dysphagia screening [5]
- Avoid early aggressive mobilization within first 24 hours (worsens 14-day mortality) [3]
- Rehabilitation activities (stretching, functional task training) may begin 24–48 hours after moderate ICH [3]
17. Disposition
Admission criteria (all ICH patients require admission)
- ICU or dedicated stroke unit admission is recommended — stroke unit care significantly reduces death/dependency (OR 0.59) [5]
- Transfer to facility with neurocritical care and neurosurgical capabilities if not available locally [3]
Neurosurgical consultation triggers
- Cerebellar hemorrhage >3 cm or >15 mL [3][9]
- Hydrocephalus requiring EVD [5]
- Large supratentorial ICH (>20–30 mL) with GCS 5–12 [9]
- Clinical deterioration with mass effect
Goals-of-care considerations
- Avoid early DNR orders or withdrawal of care in the first 24–48 hours — early prognostication is unreliable and may create a self-fulfilling prophecy [1-3]
- ICH Score should not be the sole basis for limiting life-sustaining treatments [3]
- Recovery after ICH is often delayed compared with ischemic stroke of similar severity [2]
18. Follow Up / Return Precautions
Follow-up timing
- Neurology/neurosurgery follow-up within 2–4 weeks of discharge
- Repeat brain MRI and vascular imaging at 3 months to exclude underlying lesion initially compressed by hematoma [9]
- Blood pressure monitoring and optimization — long-term BP control is the cornerstone of secondary prevention [1]
Symptoms requiring immediate reassessment
- New or worsening headache, vomiting, vision changes
- New weakness, numbness, speech difficulty
- Seizure
- Altered consciousness or confusion
- Signs of DVT/PE (leg swelling, dyspnea, chest pain)
Patient/family counseling
- Expected recovery is often slower than ischemic stroke; outcomes may need evaluation at later timepoints [2]
- Importance of medication adherence (especially antihypertensives)
- Alcohol cessation, smoking cessation, avoidance of sympathomimetic drugs
- Discuss anticoagulation resumption decisions with neurology (complex, individualized) [29]
- Multidisciplinary rehabilitation (PT, OT, speech therapy) — early supported discharge for mild-moderate ICH [3]
References
1. Spontaneous Intracerebral Hemorrhage. — Sheth KN. The New England Journal of Medicine. 2022.
2. Management of Intracerebral Hemorrhage: JACC Focus Seminar. — Schrag M, Kirshner H. Journal of the American College of Cardiology. 2020.
3. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. — Greenberg SM, Ziai WC, Cordonnier C, et al. Stroke. 2022.
4. Intracerebral Haemorrhage: Current Approaches to Acute Management. — Cordonnier C, Demchuk A, Ziai W, Anderson CS. Lancet. 2018.
5. Cerebral Intraparenchymal Hemorrhage: A Review. — Gross BA, Jankowitz BT, Friedlander RM. The Journal of the American Medical Association. 2019.
6. Clinical Syndromes and Management of Intracerebral Hemorrhage. — Ko SB, Choi HA, Lee K. Current Atherosclerosis Reports. 2012.
7. Does This Patient Have a Hemorrhagic Stroke?Clinical Findings Distinguishing Hemorrhagic Stroke From Ischemic Stroke. — Runchey S, McGee S. The Journal of the American Medical Association. 2010.
8. Discrimination of Ischemic Versus Hemorrhagic Stroke Type by Presenting Symptoms or Signs: A Systematic Review and Meta-Analysis. — McDermott CM, Seminer A, Comer S, et al. Journal of Stroke and Cerebrovascular Diseases : The Official Journal of National Stroke Association. 2025.
9. Stroke. — Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Lancet. 2024.
10. Treatment of Intracerebral Haemorrhage. — Mayer SA, Rincon F. The Lancet. Neurology. 2005.
11. 2024 AHA/ASA Performance and Quality Measures for Spontaneous Intracerebral Hemorrhage: A Report From the American Heart Association/American Stroke Association. — Ruff IM, de Havenon A, Bergman DL, et al. Stroke. 2024.
12. FDA Orange Book. — FDA Orange Book. 2026.
13. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Jones DW, Ferdinand KC, Taler SJ, et al. Journal of the American College of Cardiology. 2025.
14. Surgery for Spontaneous Supratentorial Intracerebral Haemorrhage. — Wilting FN, Sondag L, Schreuder FH, et al. The Cochrane Database of Systematic Reviews. 2025.
15. Incidence and Outcomes of Patients With Early Cardiac Complications After Intracerebral Hemorrhage: A Report From VISTA. — Ishiguchi H, Huang B, El-Bouri WK, et al. Stroke. 2024.
16. Predisposing Factors, Pathologies, and Precipitating Factors Causing Intracerebral Hemorrhage. — Hosking A, Samarasekera N, Moullaali TJ, et al. Stroke. 2026.
17. Identifying Best Practices to Improve Evaluation and Management of in-Hospital Stroke: A Scientific Statement From the American Heart Association. — Nouh A, Amin-Hanjani S, Furie KL, et al. Stroke. 2022.
18. ACR Appropriateness Criteria® Cerebrovascular Diseases-Stroke and Stroke-Related Conditions. — Pannell JS, Corey AS, Shih RY, et al. Journal of the American College of Radiology : JACR. 2024.
19. The ICH Score: A Simple, Reliable Grading Scale for Intracerebral Hemorrhage. — Hemphill JC, Bonovich DC, Besmertis L, Manley GT, Johnston SC. Stroke. 2001.
20. Optimum Baseline Clinical Severity Scale Cut Points for Prognosticating Intracerebral Hemorrhage: INTERACT Studies. — You S, Zheng D, Yoshimura S, et al. Stroke. 2024.
21. Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury: JACC State-of-the-Art Review. — Sposato LA, Hilz MJ, Aspberg S, et al. Journal of the American College of Cardiology. 2020.
22. Changes of Electrocardiogram and Myocardial Enzymes in Patients With Intracerebral Hemorrhage. — Qin G, Dai C, Feng S, Wu G. Disease Markers. 2022.
23. Intracerebral Haemorrhage Expansion: Definitions, Predictors, and Prevention. — Morotti A, Boulouis G, Dowlatshahi D, et al. The Lancet. Neurology. 2023.
24. Enhanced Prediction of in-Hospital Mortality in Intracerebral Hemorrhage: Impact of Serial Neurological and Radiological Reassessment With the ICH Score at 6 Hours Postadmission. — Meyrat R, Vivian E, Dulaney B, Barrera Gutierrez JC. Journal of Neurosurgery. 2025.
25. A Narrative Review of Cardiovascular Abnormalities After Spontaneous Intracerebral Hemorrhage. — Lele A, Lakireddy V, Gorbachov S, et al. Journal of Neurosurgical Anesthesiology. 2019.
26. The Heart-Brain-Metabolism Axis in Cardiovascular and Neurologic Disease. — Tardo DT, Cortes-Canteli M, Fuster V, Sachdev PS, Kovacic JC. Journal of the American College of Cardiology. 2025.
27. Stroke in China: Advances in Prevention and Management on the Path to a Healthy China. — Wu S, Wang Y, Liu J, et al. The Lancet. Neurology. 2026.
28. Treatment of Intracerebral Hemorrhage: From Specific Interventions to Bundles of Care. — Parry-Jones AR, Moullaali TJ, Ziai WC. International Journal of Stroke : Official Journal of the International Stroke Society. 2020.
29. Antithrombotic Treatment After Stroke Due to Intracerebral Haemorrhage. — Cochrane A, Chen C, Stephen J, et al. The Cochrane Database of Systematic Reviews. 2023.